enGene Stock (NASDAQ:ENGN)

Forecast Ownership Financials Chart

Previous Close

$1.60

52W Range

$1.40 - $12.25

50D Avg

$4.64

200D Avg

$7.17

Market Cap

$83.96M

Avg Vol (3M)

$1.55M

Beta

-0.29

Div Yield

ENGN Company Profile

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Feb 01, 2022

Website

ENGN Performance

ENGN Financial Summary

	Oct 25	Oct 24	Oct 23
Revenue	-	-	-
Operating Income	$-123.17M	$62.30M	$-26.06M
Net Income	$117.30M	$-55.14M	$-99.92M
EBITDA	$-113.80M	$-52.04M	$-94.77M
Basic EPS	$-2.29	$-1.46	$-4.24
Diluted EPS	$-2.29	$-1.46	$-4.24

Fiscal year ends in Oct 25 | Currency in USD

Peer Comparison

Ticker	Company
ACIU	AC Immune S.A.
SLN	Silence Therapeutics plc
ALT	Altimmune, Inc.
ANNX	Annexon, Inc.
ANRO	Alto Neuroscience, Inc.
LRMR	Larimar Therapeutics, Inc.
DBVT	DBV Technologies S.A.
CLLS	Cellectis S.A.
AMRN	Amarin Corporation plc
KRRO	Korro Bio, Inc.